Clinical trial · Interventional
Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer
Interest of the Immunoscore® as a Post-operative Complementary Tool for the Detection of the Risk of Recurrence in Patients With Nonmetastatic Colorectal Cancer : Prospective Cohort Comparing the Recommandation for Patient Care According to the Immunoscore® With the Standard Care Decision.
NCT04938986CI-TRIAL-00057772recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Evaluate the patient care recommandation induced by the IMMUNOSCORE® result
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Metastatic Colorectal Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IMMUNOSCORE® | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- IMMUNOSCORE®
- interventionNames
- Diagnostic Test: IMMUNOSCORE®
Primary outcomes (1)
- measure
- Number of cases where the recommendations for patient care according to the Immunoscore® are considered beneficial compared to the standard care decision
- timeFrame
- 5 years
Secondary outcomes (4)
- measure
- Replication error (RER) phenotype
- timeFrame
- 6 and 9 months
- description
- Number of cases where the Immunoscore® resultat is inconsistent with the RER phenotype
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * age between 18 and 80 inclusive; * histologically confirmed colon adenocarcinoma; * having undergone a curative resection of stage I, II or III colorectal cancer; * diagnosed T1 / T2 / T3 / T4 and N0 / N1 / N2; * eligible to receive 6 months of adjuvant chemotherapy; * having given free, informed and written consent; * agreeing to the use of a tumor sample for research purposes; * being affiliated to a social security system. Exclusion Criteria: * pregnant or breastfeeding women * legal incapacity or physical, psychological, social or geographical conditions preventing the patient from signing the consent or completing the study. * history of other solid tumor within 3 years before inclusion, with the exception of in-situ cancer of the cervix and skin cancers (basal or squamous) treated and controlled * person subject to a safeguard measure.
References
Publications (0)
Data not yet available
No reference posted for this study.